Browse News
Filter News
Found 723,077 articles
-
The approval marks the first for EoE, a chronic, progressive type 2 inflammatory disease that damages the eosinophilic esophagitis and prevents it from working properly.
-
BridgeBio Pharma and its affiliate Phoenix Tissue Repair announced positive data from their Phase II clinical trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).
-
The hold follows a serious adverse event in which a study participant died after developing possible differentiation syndrome.
-
The 25th Annual Meeting of the American Society of Gene and Cell Therapy wrapped up on Thursday. BioSpace looks at some of the highlights.
-
Bayer has terminated a two year-old partnership with Atara to develop off-the-shelf T-cell immunotherapy for high mesothelin-expressing tumors.
-
Fueled by $37 million in Series A financing, N.C.-based Inceptor Bio is advancing three, next-generation approaches to immuno-oncology, including a CAR-T program that is expected to be in the clinic next year.
-
A study conducted by Athersys' partner Healios on a potential treatment for ischemic stroke failed to meet the primary endpoint as its stock dropped 43%.
-
Rice University researchers used the foundation of CRISPR/Cas9 technology and developed “drive-and-process” arrays, or DAP for short.
-
Anyone who has dealt with inflammatory skin conditions is familiar with what seems like a near-constant itch. That could become a thing of the past if ASLAN Pharma has something to say about it.
-
The Zymeworks Board of Directors has rejected an acquisition proposal from activist investor All Blue Falcons FZE, calling the attempt “opportunistic.”
-
According to researchers at the Universite Sorbonne Paris Nord, Universite Paris-Saclay, ants can be trained to sniff out the specific odors associated with certain cancers.
-
Celebrities' struggles with breast cancer are bringing new awareness to the importance of screening - particularly because new therapies like Radius Health's elacestrant are on the horizon.
-
Life sciences organizations and companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Pancreatic transplants are difficult to pull off for Type 1 diabetes, but new technology may make it possible, and infusions of spinal fluid from young mice to older ones reportedly reverses memory loss.
-
BioSpace spoke with four veterans in the field about the less obvious reasons why companies with good science may still fail.
-
Platelet Derived Growth Factors PDGFR Inhibitors Clinical Trials Market Approval Insight 2026
5/20/2022
The introduction of targeted therapies has greatly revolutionized the overall paradigm of cancer treatment.
-
B Cell Maturation Antigen Targeted Therapy Clinical Trials Report 2026
5/20/2022
B-cell maturation target (BCMA) has recently emerged out as potential target for the development of novel immunotherapies in multiple myeloma.
-
MEK Inhibitors Clinical Trials Market Approval Insight 2026
5/20/2022
Although traditional chemotherapeutic drugs remains the first line option for the management of most cancer types, targeted cancer therapies are emerging as standard treatment for advanced stage cancers.
-
TIGIT Inhibitor Drug Clinical Trials Report 2022
5/20/2022
T-cell immunoreceptor with Ig and ITM domain (TIGIT) is novel immunological checkpoint which is being studied as potential immunotherapeutic target.
-
LAG 3 Inhibitor Clinical Research By Indication Company Insight 2028
5/20/2022
Melanoma is a form of skin cancer characterized by the uncontrolled growth of pigment-producing cells (melanocytes) located in the skin.